PROKPROKIDNEY CORP.

Nasdaq prokidney.com


$ 2.46 $ 0.04 (1.65 %)    

Friday, 28-Jun-2024 15:59:49 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 2.46
$ 2.48
$ 0.00 x 0
$ 0.00 x 0
$ 2.28 - $ 2.50
$ 1.12 - $ 13.51
3,440,533
na
149.94M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-28-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-prokidney-prices-upsized-130m-public-offering-of-53719009-class-a-ordinary-shares-at-242share-and-concurrent-registered-direct-offering

All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold...

 prokidney-corp-announces-125m-public-offering-and-concurrent-registered-direct-offering-of-class-a-ordinary-shares

30-Day Option For Underwriters To Purchase Up To An Additional 15%

 jefferies-maintains-buy-on-prokidney-lowers-price-target-to-6

Jefferies analyst Kelly Shi maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $15 to $6.

 prokidney-announces-operational-updates-and-progress-in-european-and-us-clinical-trials-for-ckd-therapy-rilparencel

ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chr...

 b-of-a-securities-maintains-neutral-on-prokidney-raises-price-target-to-4

B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and raises the price target from $...

 prokidney-q1-eps-016-remains-flat-yoy-exits-quarter-with-cash--equivalents-worth-329m

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.25) by ...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 morgan-stanley-assumes-prokidney-at-equal-weight-announces-price-target-of-3

Morgan Stanley analyst Judah Frommer assumes ProKidney (NASDAQ:PROK) with a Equal-Weight rating and announces Price Target o...